PM360

JULY 13, 2023

“People adhere to medicines at a scale that should bewilder everyone in healthcare,” exclaims Grace Lomax, Clinical Director of Patient Connect , part of Clarivate. Little wonder 70% of patients with hypertension remain hypertensive and therefore at risk of myocardial infarctions (MIs) and cerebrovascular accidents.

Patients 98

Patients Education Medical Side effects 98

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results. Then 487 were part of the BV-AVD group.

Patients 75

Patients Side effects Healthcare Healthcare 75

PM360

OCTOBER 13, 2023

HCPs need pharma, and pharma needs HCPs—so let’s make sure that this next chapter of engagement is one of partnership, in pursuit of the interest of patients.” Only 15% of prescribers think the drugs come at reasonable cost to patients or have decent insurance coverage eligibility.

Healthcare 59

Healthcare Healthcare Doctors Pharma 59

European Pharmaceutical Review

OCTOBER 21, 2022

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. A breakdown of the data showed: HbsAb levels were greater than 1000mIU/ml in 88 percent of patients.

Patients 69

Patients Food and Drug Administration Side effects Food 69

Clarify Health

OCTOBER 3, 2023

Today, there are some noticeable shifts for the better happening on the digital front, largely driven by healthcare consumerism and the demand that healthcare meet patients where they are – on their phones, in their homes, and outside the hospital. Collecting data outside of a care setting can offer valuable insights into day-to-day health.

Healthcare 59

Healthcare Healthcare Patients Side effects 59

pharmaphorum

JULY 18, 2022

That is down to the company’s ADC technology platform, which means that the cytotoxic payload that circulates systemically after administration is lower than the already-marketed ADCs and should therefore limit side effects, according to the biotech.

Side effects 57

Side effects Physicians FDA Marketing 57

European Pharmaceutical Review

MARCH 14, 2024

HTL0048149 began first-in-human clinical trials in 2023, according to an announcement by Sosei in July 2023. Sosei Heptares will receive an upfront payment of €25 million. The small molecule treatment HTL0048149 is a first-in-class GPR52 agonist with a novel mechanism of action.

Side effects 70

Side effects Sales Pharmaceutical Patients 70

European Pharmaceutical Review

DECEMBER 22, 2023

This represents a 53 percent premium on Karuna’s closing stock price on 21 December 2023. It has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments like weight gain.

Food and Drug Administration 89

Food and Drug Administration Side effects Safety Food 89

Pharmaceutical Technology

NOVEMBER 14, 2022

In September, a group from Friedrich Alexander University Erlangen-Nuremberg reported that five patients with lupus achieved remission after an infusion of autologous chimeric antigen receptor (CAR)-T cells led to a deep depletion of B cells. All five patients achieved remission after three months.

Side effects 144

Side effects Patients Manufacturing Safety 144

European Pharmaceutical Review

NOVEMBER 16, 2023

It has been conditionally authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) as a gene-editing therapy for certain patients 12 years old and over with sickle-cell disease and transfusion-dependent β-thalassemia. Side effects from treatment were similar to those associated with autologous stem cell transplants.

Safety 88

Safety Side effects Medicine Patients 88

European Pharmaceutical Review

NOVEMBER 3, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Pfizer’s Litfulo (ritlecitinib) for treatment for severe alopecia areata in patients 12 years and older. A hard capsule medicine, Litfulo is recommended to be taken daily as one 50mg oral dose. Litfulo’s active ingredient, ritlecitinib, is an enzyme inhibitor.

Food and Drug Administration 79

Food and Drug Administration Side effects Medicine Food 79

European Pharmaceutical Review

APRIL 20, 2023

This is according to results from a preliminary study, of which the abstract will be presented at the American Academy of Neurology’s 75th Annual Meeting held between April 22-27 2023. Results from a Phase III study evaluating migraine patients given 10mg, 30mg and 60mg of atogepant were published in 2021.

Side effects 80

Side effects Safety Medical Pharmaceutical 80

pharmaphorum

SEPTEMBER 16, 2022

Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable stress in the daily lives of patients and often negatively affect their day-to-day and long-term well-being. However, side effects do happen.

Management 71

Management Side effects Patients Safety 71

Pharma Leaders

MAY 18, 2023

The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy.

Food and Drug Administration 52

Food and Drug Administration FDA Side effects Prospecting 52

European Pharmaceutical Review

APRIL 6, 2023

For breast cancer patients, the treatment is approved for those who have inherited faults in their BRCA1 or BRCA2 genes, after surgery and chemotherapy and are HER2-negative and at high-risk. Following this recommendation, 300 BRCA-positive HER2-negative high-risk early breast cancer patients will now be eligible to be treated with olaparib.

Side effects 74

Side effects Medicine Patients Pharmaceutical 74

European Pharmaceutical Review

JANUARY 25, 2024

Within the EU, patient information leaflets (PILs) are not merely a regulatory requirement but a cornerstone of patient safety. They detail the medication’s intended use, proper administration, potential side effects and precautions. percent as EU average with some Member States as high as 25 percent).

Healthcare 76

Healthcare Healthcare Electronics Safety 76

pharmaphorum

OCTOBER 27, 2022

Santhera has completed a rolling application for its Duchenne muscular dystrophy (DMD) therapy vamorolone in the US, setting up a possible approval and launch in the latter half of 2023. “We look forward to working closely with US regulators to advance vamorolone towards approval,” he added.

FDA 82

FDA Side effects Biopharma Marketing 82

Pharmaceutical Technology

JUNE 5, 2023

It has also been approved in the US to treat symptomatic New York Heart Association class II-III obstructive HCM in adult patients, improving their functional capacity and symptoms. The treatments currently used to try to manage symptoms are associated with side effects and are often ineffective.

Side effects 52

Side effects Medicine Management Patients 52

Pharmaceutical Technology

APRIL 21, 2023

The company will make a $20m upfront payment, which includes $6m paid at closing and an additional $4m payment in the fiscal year 2023. Our core mission of helping patients in need remains strong and steadfast, and we look forward to developing this asset and our pipeline for patients around the world.”

Food and Drug Administration 52

Food and Drug Administration Side effects Distribution Food 52

European Pharmaceutical Review

OCTOBER 12, 2022

A Phase III trial evaluating TauRx Therapeutics’ oral drug hydromethylthionine mesylate (HMTM), a tau aggression inhibitor, showed the medication continued to improve cognition over a pre-treatment baseline in patients with early Alzheimer’s for the first time. The safety data from the trial was consistent with earlier trial data.

Side effects 82

Side effects Safety Patients Sales 82

European Pharmaceutical Review

JANUARY 11, 2024

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. The present unmet needs within chronic pain are not met with opioid therapies.

Medicine 73

Medicine Pharmacology Management Side effects 73

Pharmaceutical Technology

APRIL 14, 2023

NASH is a form of nonalcoholic fatty liver disease (NAFLD), where patients develop excess fat in their liver. Alongside increased liver fat, NASH patients suffer from liver inflammation and damage that can eventually lead to fibrosis. Madrigal expects to file an NDA for the drug in H1 2023, based on a February 2023 company update.

Side effects 52

Side effects Patients Leads Pharmaceutical 52

Pharmaceutical Technology

MAY 26, 2023

It follows a March 2023 FDA Advisory Committee meeting where panelists voted 16-1 in favour of the drug’s approval. However, upon Paxlovid’s widespread use, some patients reached full recovery from Covid-19 only to test positive again or have a relapse in symptoms within a few days or weeks. This phenomenon was coined Paxlovid rebound.

Food and Drug Administration 59

Food and Drug Administration FDA Side effects Safety 59

Pharmaceutical Technology

JUNE 1, 2023

For context, in January 2023, the FDA accepted Intercept’s resubmission of its NDA for OCA as a Class 2 resubmission (which has a six-month review period in NASH) and set a Prescription Drug User Fee Act (PDUFA) date of 22 June 2023. risk reduction compared with placebo).

FDA 52

FDA Side effects Prescription Patients 52

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Food and Drug Administration 98

Food and Drug Administration Side effects Pharmaceutical Leads 98

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). Up to fifty percent of IgAN patients progress to end-stage renal disease, requiring dialysis or transplant.

Food and Drug Administration 89

Food and Drug Administration Side effects Leads Patients 89

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). Up to fifty percent of IgAN patients progress to end-stage renal disease, requiring dialysis or transplant.

Food and Drug Administration 88

Food and Drug Administration Side effects Leads Patients 88

Pharmaceutical Technology

JUNE 16, 2023

Since some of the patients with major clinical depression do not respond sufficiently to one or more antidepressants, there is a need for new treatments, said Buntinx. Due to this, adjunctive treatments are used as part of a patient’s treatment regimen. While the drug is marketed in other countries, it is not registered in the US.

Food and Drug Administration 52

Food and Drug Administration Side effects Safety Recruitment 52

European Pharmaceutical Review

DECEMBER 14, 2023

They also include many of the common “exclusions” in RCTs, such as pregnant women, children, the elderly and patients on multiple medications. As of October 2023, 62.93 million patients were registered with GP practices in England, which hold health information about each person “from the cradle to the grave”. cited Dec2023].

Safety 108

Safety Medicine Competition Networking 108

PM360

JULY 13, 2023

Here are twelve of the best examples of programs, strategies, solutions, technology, and more that companies have developed or are using to keep patients on their prescribed therapies. But outdated manual processes are complex and leave many patients out. But outdated manual processes are complex and leave many patients out.

Education 89

Education Medical Media Patients 89

Pharmaceutical Technology

APRIL 24, 2023

The British institute that oversees a therapy’s cost-effectiveness opted for the recommendation based on clinical data from the Phase II CAPTIVATE and the Phase III GLOW studies. The combination therapy also caused fewer side effects, with heart problems and hypertension as the most common ones, based on the final draft guidance.

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

pharmaphorum

DECEMBER 13, 2022

Krazati has been cleared as a treatment for patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) after one prior systemic therapy – the same indication given to Amgen’s Lumakras (sotorasib) when it became the first KRAS inhibitor to be approved in the US in May 2021.

FDA 52

FDA Side effects Competition Patients 52

pharmaphorum

OCTOBER 11, 2022

Treatment options for patients with APDS are currently limited to antibiotics for infections and immunoglobulin replacement therapy to prop up their immune systems. The filings are based on a 31-patient phase 2/3 trial which showed that the PI3K? The post Pharming files rare disease drug leniolisib in Europe appeared first on.

Side effects 52

Side effects Competition Prospecting Sales 52

Pharmaceutical Technology

APRIL 24, 2023

While 80% of the world’s population practices some form of traditional medicine, according to the World Health Organization (WHO), the practice is regularly discredited due to a lack of scientific support and regulation as well as evidence of negative side effects with certain medicines.

Medicine 105

Medicine Side effects Healthcare Healthcare 105

Pharmaceutical Technology

AUGUST 26, 2022

Last week, the collaborative announced that it is executing a joint development agreement (JDA) to advance two novel drug regimens to Phase II clinical trials by 2023. Each trial will recruit approximately 500 patients. Following this, patients must receive follow-ups to ensure that they do not have a post-treatment relapse.

Side effects 98

Side effects Pharmaceutical Patients Recruitment 98

Pharmaceutical Technology

APRIL 13, 2023

Many of the GLP-1RAs are used off-label and are mainly indicated for patients with type 2 diabetes (T2D). Improved awareness of the risks of obesity and disease progression may also help improve access to resources and treatment available for patients with obesity.

Marketing 52

Marketing Side effects Physicians Management 52

PM360

AUGUST 9, 2022

How can we help ensure patients continue to take their medications as prescribed? The reasons why a patient may not take their medication are plentiful, and as a result so are the solutions now available to attempt to solve this issue. But it is not a simple answer. Furthermore, it is estimated to reach $6.5

Prescription 105

Prescription Medical Side effects Patients 105